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Ron, the tyrosine kinase receptor formacrophage-stimulating
protein is responsible for proliferation and migration of cells
from different tissues. Ron can acquire oncogenic potential by
single point mutations in the kinase domain, and dysregulated
Ron signaling has been involved in the development of different
humancancers.Wehavepreviously shown that ligand-activated
Ron recruits the negative regulator c-Cbl, which mediates its
ubiquitylation and degradation. Here we report that Ron is
ubiquitylated also by the U-box E3 ligase C-terminal Hsc70-in-
teracting protein (CHIP), recruited via chaperone intermediates
Hsp90 and Hsc70. Gene silencing shows that CHIP activity is
necessary to mediate Ron degradation upon cell treatment with
Hsp90 inhibitors geldanamycins. The oncogenic RonM1254T
receptor escapes from c-Cbl negative regulation but retains a
strong association with CHIP. This constitutively active mutant
of Ron displays increased sensitivity to geldanamycins,
enhanced physical interaction with Hsp90, andmore rapid deg-
radation rate. Cell growth and migration, as well as the trans-
forming potential evoked by RonM1254T, are abrogated upon
Hsp90 inhibition. These data highlight a novel mechanism for
Ron degradation and propose Hsp90 antagonists like geldana-
mycins as suitable pharmacological agents for therapy of can-
cers where altered Ron signaling is involved.
Dysregulated activation of receptor tyrosine kinases (RTKs)3
has been extensively documented in different types of human
tumors (1) and frequently correlates with poor responsiveness
to conventional therapies, pointing at RTKs as potential targets
for molecule-based cancer therapy (2, 3). Among the different
therapeutic approaches a promising strategy relies on forcing
RTKs toward degradative pathways (4).
The Ron tyrosine kinase, receptor for macrophage-stimulating
protein (MSP), is amemberof thehepatocytegrowth factor (HGF)
receptor subfamily (5, 6). Ron is expressed in a variety of human
tissues, and the engagement by its cognate ligand activates multi-
ple intracellular signaling pathways controlling normal cell prolif-
eration,migration, and adhesion-dependent survival (7–9). A sin-
gle point mutation (M1254T), targeted to a conserved residue of
the tyrosine kinase domain is oncogenic (RonM1254T), by increas-
ing kinase efficiency and subverting substrate specificity (10, 11).
Growing evidence indicates that Ron can be involved in cancer
development and progression in humans (12, 13) and inmurine
models (14, 15). Therefore, targeting Ron expression by forcing
its down-regulation may help to elucidate its role in tumor
development and progression.
It has been reported that many kinases that are deregulated
in human cancers are dependent on the chaperone activity of
the Heat shock protein 90 (Hsp90) for their conformational
maturation and stability (16). Hsp90 is a ubiquitous chaperone
protein abundantly expressed inmammalian cells, where it per-
forms housekeeping functions assisting in the folding, activa-
tion, and assembly of a variety of proteins (17). Hsp90 functions
in concert with several co-chaperone proteins thatmodulate its
chaperone activity (18). The co-chaperone E3 ubiquitin ligase
C-terminal Hsc70-interacting protein (CHIP) has been
reported to participate in Hsp90 multichaperone complexes,
being involved in ubiquitylation and degradation of client pro-
teins (19, 20).
Geldanamycins are a class of benzoquinone ansamycin anti-
biotics, able to compete with ADP/ATP in the nucleotide bind-
ing pocket of Hsp90, inhibiting its ATP-dependent chaperone
activity and thus directing the ubiquitin-mediated proteasomal
degradation of the client proteins (21, 22). By leading to deple-
tion of important effector proteins that contribute to deregu-
lated signaling, geldanamycin (GA) and its less toxic derivative
17-allylamino-17-demethoxygeldanamycin (17-AAG) exhibit
potent anti-tumor activity against human cancer cells, both
in vitro and in tumor xenografts (23, 24). Indeed, based on
promising preclinical evaluations, 17-AAG is currently in clin-
ical trials as a single agent or in combination with other chemo-
therapeutics (25, 26).
Sensitivity to benzoquinone ansamycins has been described
for several RTKs. It has been reported that treatment of breast
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and other cancer cells with GA causes rapid ubiquitylation of
cell surface HER2/ErbB2 molecules, followed by their
proteasome-dependent degradation (27). A recent study dem-
onstrated the ability of GA to deplete mature EGFR protein
harboring kinase domain mutations (28). Moreover, geldana-
mycins have been shown to down-regulate the HGF receptor
(Met) and to prevent HGF-mediated tumor cell motility and
invasion (29, 30).
We have previously shown that activated Ron recruits to its
multifunctional docking site the negative regulator c-Cbl,
which mediates ligand-dependent Ron ubiquitylation and
down-regulation, through its E3 ubiquitin ligase activity (31).
Here we report that Ron forms amultichaperone complex con-
taining Hsp90, Hsc70, and the E3 ligase CHIP. We also show
that GA and its derivative 17-AAG induce degradation of both
precursor and membrane-exposed forms of Ron. This occurs
by impairing Ron association with Hsp90 and by promoting
CHIP-mediated receptor ubiquitylation.
The oncogenic RonM1254T escapes from c-Cbl-mediated
negative regulation but is efficiently destabilized by geldanamy-
cins, which hinder growth and migration as well as transform-
ing activity of the oncogenic receptor.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Geldanamycin, 17-AAG, MG-132,
and concanamycin A were purchased from Alexis (Montreal,
Canada). Human recombinant MSP was obtained by R&D Sys-
tems (Minneapolis,MN).Polyclonal antibodies againstRonC-ter-
minal domain (c-20) and monoclonal anti-Hsc70 (B-6) were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Monoclonal anti-Hsp90 antibody was from BD Transduction
Laboratories; monoclonal anti--tubulin (B-5-1-2), anti-phos-
pho-Erk1/2 (MAPK-YT), and anti-FLAG (M2) were from Sigma;
polyclonalphospho-Akt (Ser473)was fromCell SignalingTechnol-
ogy (Beverly,MA);monoclonal anti-Cbl (7G10)was fromUpstate
Biotechnology, Inc. (Charlottesville, VA), monoclonal anti-ubiq-
uitin (FK2) was from Stressgen (San Diego, CA); and CHIP rabbit
polyclonal antiserumwas fromCalbiochem (Merck).Horseradish
peroxidase-conjugated anti-mouse and anti-rabbit were pur-
chased fromGEHealthcare (Uppsala, Sweden).
Preparation of Plasmid Constructs—pMT2-Ron and pMT2-
RonM1254T were described previously (10). c-Cbl, c-Cbl70z,
CHIP, CHIPK30A, and CHIPU-box were prepared in
pcDNA3 (32, 33). GST-CHIP and GST-CHIPU-box in
pGEX4T-2 vector were kindly provided by Dr. H. Band
(Brigham and Women’s Hospital, Boston, MA). pCCLsin-
.PPT.hPGK.GFP.Wpre transfer plasmid was used to express
two independent small interfering RNAs (siRNAs) (5-ACCA-
CGAGGGTGATGAGGA-3 and 5-GAAGCGAGATATCC-
CTGAC-3), targeting CHIP transcripts or an unrelated
FIGURE 1. Geldanamycins induce degradation of both precursor and
mature cell surface Ron. A, 3T3-Ron and FG2 cells were treated with vehicle
() or 1 M GA or 1 M 17-AAG for the indicated times. Cell lysates were
analyzed by immunoblotting (IB) with a polyclonal antibody against Ron
C-terminal domain, recognizing both the 170-kDa precursor and the 150-kDa
-chain of the receptor.-Tubulin immunoblottingwas used as loading con-
trol. B, 3T3-Ron and FG2 cellswere cell surface-biotinylated and then cultured
in medium with vehicle () or 1 M GA, or 1 M 17-AAG for 6 h. After immu-
noprecipitation (IP) of cell lysates with streptavidin-Sepharose, surface-la-
beled mature Ron was detected by anti-Ron immunoblotting. All results
shown are representative of at least four independent experiments.
FIGURE 2. The ubiquitin-proteasome pathway is involved in Ron degra-
dation induced by geldanamycins. A, proteins from lysates of 3T3-Ron and
FG2 cells treatedwith vehicle () or 1MGA, or 1M 17-AAG for 15minwere
immunoprecipitated with Ron antibodies. Anti-ubiquitin immunoblotting
(IB) was used to detect the ubiquitylated receptor molecules. The immuno-
precipitated (IP) receptor was detected by Ron immunoblotting. B, 3T3-Ron
and FG2 cells were treated with vehicle () or 1M GA or 1M 17-AAG in the
presence or absence of the proteasome inhibitor MG-132 (20 M). Cells were
incubated with MG-132 for 1 h before drug addition. Equal quantities of
lysates from cells harvested at the indicated timeswere analyzed by anti-Ron
immunoblotting. Anti--tubulin immunoblotting was used as loading con-
trol. Representative results from three independent experiments are shown.
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sequence as negative control. The expression was under the
transcriptional control of the H1 promoter derived from pSU-
PER plasmid (34). The vector carries an independent GFP
expression cassette, to allow for the identification of transfected
cells.
Cell Culture and Transfection—Cells were purchased from
American Type Culture Collection. FG2 cells were maintained
in RPMI 1640, COS-7, and NIH-3T3 cells in Dulbecco’s modi-
fied Eagle’s medium (Sigma), supplemented with 10% fetal
bovine serum (Invitrogen) in a 5% CO2-humidified atmo-
sphere. NIH-3T3 cells stably expressing Ron or RonM1254T
were obtained as described previously (10). Transient trans-
fection of COS-7 cells was performed with DEAE-dextran
using the CellPhect transfection kit (GE Healthcare). Lipo-
fectaminePlus (Invitrogen) was used for transfection of FG2
cells with siRNAs constructs according to the manufactur-
er’s recommendations.
Immunoprecipitation and Immunoblotting—Total cellular
proteins were extracted by solubilizing the cells in radioim-
mune precipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS)
containing protease and phosphatase inhibitors (10 g/ml
aprotinin, 10g/ml leupeptin, 10g/ml pepstatin, 1 mM phen-
ylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 2
mM sodium fluoride). Whole-cell lysates were clarified by cen-
trifugation (14,000 g, 10 min), quantified with the BCA pro-
tein assay reagent kit (Pierce) and dissolved in Laemmli sample
buffer. For immunoprecipitation, cells were lysed in solubiliza-
tion buffer (20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 150 mM
NaCl, 10% glycerol, 1% Triton X-100) with protease inhibitors.
500-g aliquots of clarified cell lysates were incubated with 1
g of the indicated antibody immobilized on protein A-Sepha-
rose 4B packed beads (GE Healthcare) for 2 h at 4 °C. After
extensive washes with lysis buffer, precipitated proteins were
dissolved in Laemmli sample buffer. Proteins were resolved by
10% SDS-PAGE, transferred to nitrocellulose membrane, and
probed with respective antibodies. For ubiquitin immunoblot-
ting, proteins were transferred to polyvinylidene difluoride
membranes, incubated for 30 min in 20 mM Tris-HCl contain-
ing 6 M guanidine hydrochloride and 5mM 2-mercaptoethanol,
and then probed with ubiquitin antibodies. Detection was per-
formed by the ECL system (GE Healthcare) and the Chemidoc
exposure system (Bio-Rad). Image analysis was performed with
Quantity One (Bio-Rad).
In Vitro Ubiquitylation Assay—The GST-CHIP and GST-
CHIPU-box fusion proteins were expressed in E. coli and
affinity-purified as described by the manufacturer’s protocol.
Receptors were immunoprecipitated from 800-g aliquots of
cell lysates with protein A-Sepharose beads. Following purifi-
cation, Sepharose beads were extensively washed and incu-
bated in a 50-l reaction for 90 min at 37 °C with 275 ng of
purified E1, 400 ng of E2 (UbcH5a), 5 ng/l biotin NH2-termi-
nal ubiquitin, 10 ng/l ubiquitin (Boston Biochem Inc., Cam-
bridge, MA), and 5g of the indicated GST fusion proteins in a
buffer containing 50mMTris-HCl, pH 7.5, 2.5mMMgCl2, 2mM
ATP, 2 mM dithiothreitol. After extensive washes the ubiquity-
lated receptors were detected by SDS-PAGE andWestern blot-
ting with horseradish peroxidase-conjugated streptavidin (GE
Healthcare).
Cell Surface Biotinylation Assay—Surface proteins were
labeled for 30 min at 4 °C with 0.5 mg/ml Ez-Link sulfo-NHS-
Biotin (Pierce) in buffer A (1.3 mM CaCl2, 0.4 mM MgSO4-
7H2O, 5 mM KCl, 138 mM NaCl, 5.6 mM D-glucose, 25 mM
HEPES, pH 7.4). After extensive washes with Dulbecco’s mod-
ified Eagle’s medium containing 0.6% bovine serum albumin
and 20 mM HEPES, pH 7.4, cells were lysed, and proteins were
subjected to immunoprecipitationwith streptavidin-Sepharose
(GEHealthcare). Protein samples were analyzed by SDS-PAGE
and immunoblotting.
Cell Proliferation Assay—Cells were plated on 96-well plates
at a density of 4 104/well and cultured in appropriatemedium
supplemented with 10% fetal bovine serum in the presence or
absence of 100 nM 17-AAG. Cells were fixed in 11% glutaralde-
hyde 0, 24, 48, and 72 h after drug addition and stained in crystal
violet. Staining was solubilized in 10% acetic acid, and absorb-
ance at 595 nm was measured with a microplate reader.
Cell Migration Assay—Cell motility was assayed using 8-m
pore size Transwell chambers (CorningGlass). The lower side
of the membrane was coated with 10 g/ml fibronectin for 2 h
and then blocked with 0.2% bovine serum albumin. Cells were
FIGURE3.CHIPservesasanE3 ligase forRonand interactswith thereceptor
by a chaperone intermediate. A, COS-7 cells were transiently transfected with
Ron and either CHIP or different CHIPmutants. 72 h after transfection, cells were
lysed, and equal protein amounts were immunoprecipitated (IP) with Ron anti-
bodies. Association of Hsp90, Hsc70, and CHIP to the Ron immunocomplex
was detected with the appropriate antibodies. Anti-CHIP immunoblotting
(IB) of cell lysates was used to control transfection efficiency. B, proteins from
3T3-Ron cell lysateswere immunoprecipitatedwith Ron antibodies or preim-
mune rabbit serum. Immunoprecipitates were subjected to in vitro ubiquity-
lationassay in thepresenceofGSTorGST-CHIP fusionproteins, biotin-labeled
ubiquitin, E1 and E2 enzymes. The ubiquitylated receptors were detected by
Western blottingwith streptavidin-horseradish peroxidase. All results shown
are representative of at least three independent experiments.WT, wild type.
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detached with 1 mM EDTA and resuspended with 2% fetal
bovine serum. 1  105 cells were plated on the upper side and
allowed to migrate for 6 h in the presence of 100 nM 17-AAG
toward the lower chamber containing appropriate medium sup-
plemented with 10% fetal bovine serum. Cells remaining in the
upper chamber were mechanically removed, and those that
migrated to the lower side were fixed and stained as described
above.
Transforming Assay—A focus-forming assay was performed
on NIH-3T3 fibroblasts (5  105 cells) with 5 g of recombi-
nant plasmid as described previ-
ously (10). Two days after transfec-
tion, 17-AAGwas added to cultures
and renewed every 48 h. Cell cul-
tures were maintained at conflu-
ence and screened for focus forma-
tion 10 18 days after transfection.
Spontaneous formation of foci was
negligible.
RESULTS
Geldanamycins Target Ron for
Degradation—To investigate the sen-
sitivity of Ron toHsp90 inhibitors, we
performed a time course experiment
on NIH-3T3 fibroblasts (3T3-Ron)
and pancreatic carcinoma FG2 cells,
expressing recombinant and endoge-
nous Ron, respectively. After cell
exposure to GA for different times,
we observed a robust reduction of
both precursor and mature form of
the receptor within 6 h. It is notewor-
thy that Ron protein levels declined
with similar rates in both cell lines
uponGAtreatment. Similar effects, at
a slightly lesser extent, were observed
with the same concentration of the
less toxicGAderivative 17-AAG (Fig.
1A). Ron destabilization upon Hsp90
inhibition was obtained also by using
a chemically unrelated Hsp90 inhibi-
tor, the macrolactone antibiotic radi-
cicol (supplemental Fig. 1).
It has been shown for other RTKs
(platelet-derived growth factor
receptor and epidermal growth fac-
tor receptor) (35) that only the
newly synthesized receptor mole-
cules are destabilized by GA. We
evaluated if Ron depletion following
GA or 17-AAG exposure was due to
impaired maturation of the nascent
chains only or if also cell surface-ex-
posed receptors were targeted for
degradation. By surface biotinyla-
tion of 3T3-Ron and FG2 cells, fol-
lowed by Ron immunoprecipita-
tion, we observed an accelerated decrease of cell surfacemature
Ron after exposure to GA or 17-AAG for 6 h (Fig. 1B). This
indicates that GA and 17-AAG, albeit with minor efficacy, are
able to destabilize the receptor even after its exposure to the
plasmamembrane. InNIH-3T3 cells expressing a kinase-defec-
tive Ron mutant (31), GA-induced receptor degradation was
retained (supplemental Fig. 2), demonstrating that the kinase
activity is not required for sensitivity of Ron to GA.
GA-induced degradation of the client proteins is reported to
involve the ubiquitin-proteasome pathway (36). Thus, we ana-
FIGURE 4. The ubiquitin ligase activity of CHIP is necessary to mediate Ron degradation induced by
geldanamycins. A, COS-7 cells were transiently transfected with Ron and either CHIP or the ubiquitylation-
defective CHIPU-box. 72 h after transfection, cells were treatedwith vehicle () or 1MGA for 6 h and equal
amounts of cell lysates were analyzed by immunoblotting (IB) with Ron and CHIP antibodies. Representative
results from three independent experiments are shown. B, COS-7 cells were transiently transfected with Ron
and either c-Cbl or c-Cbl-70Z. 72 h after transfection, lysates from cells treated with vehicle () or 1 M GA for
6 h were analyzed by immunoblotting with Ron and c-Cbl antibodies. Representative results from two inde-
pendent experiments are shown. C, FG2 cells were transiently transfected with siRNAs targeted to CHIP tran-
script or to anunrelated sequence. 48hafter transfection, cellswere treatedwith vehicle () or 1MGAor 1M
17-AAG. Equal quantities of lysates from cells harvested at the indicated times were analyzed by immunoblot-
ting with Ron antibodies. CHIP silencing was verified by immunoblotting with appropriate antibodies and
anti--tubulin immunoblotting was used as loading control. Densitometry of Ron immunoblotting was per-
formed and values, normalized to the relative-tubulin control bands, were plotted as percentages of vehicle-
treated cells. White columns, unrelated siRNA; black columns, CHIP siRNA. Each data point represents the
mean S.E. of three independent experiments.
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lyzed Ron ubiquitylation upon GA or 17-AAG treatment of
3T3-Ron and FG2 cells. In these conditions, a marked ubiqui-
tylation of the receptor was observed as early as 15 min after
drug addition (Fig. 2A). This indicates that receptor ubiquity-
lation is an early step in GA-induced Ron degradation and sug-
gests that a specific E3 ligase is involved. Moreover, pretreat-
ment of both cell lines with the proteasome inhibitor MG-132
impaired Ron depletion induced by geldanamycins (Fig. 2B),
indicating that this destabilizing effect on Ron requires protea-
somal activity. Conversely, when cells were pretreated with
the lysosomal inhibitor concanamycin A, GA retained full
activity on Ron (supplemental Fig. 3). Our results show that
cell surface-exposed mature Ron is destabilized by GA-in-
duced kinase-independent degra-
dation, involving the ubiquitin-pro-
teasome pathway.
Ron Associates with a Chaper-
one Complex Containing the E3
Ubiquitin Ligase CHIP—We aimed
at identifying the ubiquitin ligase re-
sponsible for GA-induced Ron
ubiquitylation. Among several li-
gases, we focused our attention on
CHIP, since this E3 enzyme medi-
ates degradation of signaling pro-
teins, relying on the associationwith
chaperone proteins Hsp90 and
Hsc70 (20, 37). We verified if Ron
and CHIP were recruited in stable
complexes with these chaperone
proteins. We co-transfected COS-7
cells with cDNAs encoding both
Ron and CHIP. Immunoblotting
analysis on Ron immunoprecipi-
tates demonstrated that the recep-
tor associates with endogenous
Hsp90 and Hsc70 as well as with
CHIP (Fig. 3A).
CHIP has the ability to bind
Hsc70 by means of the amino-ter-
minal tetratricopeptide domain,
whereas its E3 ubiquitin ligase activ-
ity is mediated by its carboxyl-ter-
minal U-box domain (38). To bet-
ter characterize the interaction
between the receptor and the ubiq-
uitin ligase, we tested the ability of
CHIP proteins harboring a muta-
tion in the tetratricopeptide (K30A)
or lacking the U-box (U-box)
domain to interact with Ron. The
K30A mutant, which does not bind
to either Hsp90 orHsc70 (20), failed
to co-immunoprecipitate with Ron.
This suggests that these chaperone
intermediates are involved in the
Ron-CHIP interaction. Conversely,
the deletion of the U-box domain
did not impair the complex formation (Fig. 3A).
To verify whether CHIP could directly mediate Ron ubiq-
uitylation, we performed an in vitro ubiquitylation assay on
immunocomplexes from 3T3-Ron fibroblasts, by using puri-
fied GST-CHIP fusion proteins in the presence of biotiny-
lated ubiquitin and E1 and E2 enzymes. Wild type (GST-
CHIP), but not U-box-deleted (GST-CHIPU-box), fusion
protein catalyzed the receptor ubiquitylation. No ubiquity-
lation was observed in the presence of GST protein alone as
well as when the reaction was performed in absence of
immunoprecipitated Ron (Fig. 3B). This demonstrates that
CHIP can serve as an E3 ligase for Ron. Taken together, these
results indicate that in live cells Ron forms a complex with
FIGURE 5. CHIP mediates c-Cbl independent oncogenic RonM1254T ubiquitylation. A, COS-7 cells were
transiently transfected with Ron or RonM1254T, along with c-Cbl and FLAG-tagged ubiquitin. 72 h after trans-
fection, serum-starved cells were treated with vehicle () or 300 ng/ml MSP for 20 min, and equal protein
amounts of cell lysates were immunoprecipitated (IP) with Ron (top) or c-Cbl (bottom) antibodies. Associated
c-Cbl or Ron were detected with the appropriate antibodies. B, Ron immunoprecipitation described in A was
followedby immunoblotting (IB) with FLAG antibodies to detect ubiquitylated receptors. The immunoprecipi-
tated receptor was detected by Ron immunoblotting. C, proteins from cell lysates of COS-7 transiently trans-
fected with RonM1254T and FLAG-tagged ubiquitin, along with CHIP or CHIPU-box or empty vector, were
subjected to immunoprecipitationwith Ron antibodies and analyzed by anti-FLAG and anti-Ron immunoblot-
ting. Anti-CHIP immunoblotting on cell lysates was used to control transfection efficiency.D, COS-7 cells were
transiently transfectedwith Ronor RonM1254T alongwithCHIP. 72 h after transfection equal protein amounts of
cell lysateswere immunoprecipitatedwith Ron or CHIP antibodies and presence of CHIP, Ron, Hsp90, or Hsc70
in the immunocomplexes was detectedwith the appropriate antibodies. Ron, RonM1254T, and CHIP expression
was monitored by immunoblotting. All results shown are representative of at least three independent
experiments.
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the chaperones Hsp90 and Hsc70, which mediate receptor
association with the E3 ubiquitin ligase CHIP.
CHIPMediates Ron Degradation Induced by Geldanamycins—
Weevaluated the involvement ofCHIP inGA-inducedRondeg-
radation by usingCOS-7 cells expressing thewild-type E3 ligase
or the deletion mutant CHIPU-box, which despite its lack of
ubiquitin ligase activity still associates with the receptor. Over-
expression of the dominant negative CHIPU-box resulted in
abrogation of GA-induced Ron degradation (Fig. 4A).
We previously reported that the E3 ubiquitin ligase c-Cbl
physically interacts with Ron, promoting its ligand-dependent
ubiquitylation and down-regulation (31). To verify the role for
c-Cbl in receptor destabilization driven by GA, we performed
the parallel experiment in COS-7 transfected with c-Cbl or the
dominant negative c-Cbl-70Z (39). Impairment of c-Cbl activ-
ity had no effect on GA-induced Ron degradation (Fig. 4B).
To confirm the key role of CHIP in GA-mediated Ron desta-
bilization, we analyzed cells deprived of CHIP by expression of
targeted siRNAs. FG2 cells were engineered by means of vec-
tors to express siRNAs designed to selectively inactivate CHIP
transcripts or targeted to an unrelated sequence as control.
Cells expressing CHIP-targeted
siRNAsdisplayedmarkedly reduced
levels of CHIP. In these conditions,
Ron was refractory to the degrada-
tion induced byGA, whereas in cells
expressing control siRNAs, recep-
tor degradation still occurred. Sim-
ilar results were obtained with the
same concentration of 17-AAG
(Fig. 4C). We conclude that the
ubiquitin ligase activity of CHIP is
necessary to mediate Ron degrada-
tion induced by geldanamycins.
CHIP Is Responsible for Onco-
genic RonM1254T c-Cbl-independent
Ubiquitylation—We next addressed
the role of CHIP-chaperone complex
on the negative regulation of the
oncogenic mutant RonM1254T. This
mutant harbors a point mutation
responsible for constitutive activation
of the kinase and for overcoming the
requirement for the multifunctional
docking site of the Ron receptor
(10, 11).
InCOS-7 cells co-expressing c-Cbl
and RonM1254T, the mutant receptor
failed to co-immunoprecipitate the
ubiquitin ligase, evenuponMSPstim-
ulation. Likewise, in the reciprocal
experiment, wild-type Ron, but not
RonM1254T, was present in c-Cbl
immunoprecipitates of the same cells
(Fig. 5A).On thebasis of these results,
we evaluated if the lack of association
with c-Cbl could affect RonM1254T
ubiquitylation. In COS-7 cells co-
transfected with wild-type or mutant receptor along with c-Cbl
and a tagged form of ubiquitin (FLAG-Ub), the ubiquitylation of
RonM1254T was preserved and was ligand-independent (Fig. 5B).
To verify if RonM1254T ubiquitylation in vivo relies on the
ubiquitin ligase activity of CHIP, we overexpressedCHIP or the
defective ligase CHIPU-box in COS-7 cells. Endogenous
CHIP was sufficient to promote RonM1254T ubiquitylation,
which was increased by overexpression of recombinant CHIP
and almost totally abrogated in cells overexpressing CHIP
U-box. This demonstrates that CHIP is a functional E3 ubiq-
uitin ligase for this oncogenic receptor (Fig. 5C).
On the basis of these data, we sought evidence of the associ-
ation of RonM1254T with the chaperone complex containing
CHIP. We co-transfected COS-7 cells with cDNAs encoding
either RonM1254T or wild-type Ron and CHIP. Hsp90, Hsc70,
and CHIP were more abundant in Ron immunocomplexes
from cells expressing the oncogenic receptor, and the stronger
interaction between CHIP and RonM1254T was confirmed by
the reciprocal experiment (Fig. 5D).
These data altogether indicate that Ron and RonM1254T dif-
ferentially interact with the E3 ligase CHIP, which is responsi-
FIGURE 6. Oncogenic RonM1254T displays higher sensitivity to geldanamycins than wild-type recep-
tor. A, 3T3-Ron and 3T3-RonM1254T cells were treated with vehicle () or 1 M GA, or 1 M 17-AAG for the
indicated times. Equal amounts of cell lysates were analyzed by immunoblotting (IB) with Ron, phospho-
Akt, and phospho-Erk1/2 antibodies. -Tubulin immunoblotting was used as loading control. B, 3T3-Ron
and 3T3-RonM1254T cells treated with vehicle () or increasing amounts of GA, or of 17-AAG for 6 h. Equal
amounts of cell lysates were analyzed by immunoblotting with Ron antibodies. Anti--tubulin immuno-
blotting was used as loading control. All results shown are representative of at least four independent
experiments.
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ble for the c-Cbl- and ligand-independent ubiquitylation of the
oncogenic receptor.
Oncogenic M1254T Substitution Increases Ron Sensitivity to
Geldanamycins—Since oncogenic RonM1254T is recruited into
the CHIP-chaperone complex even more efficiently than wild-
type Ron, we tested the activity of GA and 17-AAG on the
stability of the wild-type receptor and of its oncogenic
counterpart.
The treatment of 3T3-Ron and 3T3-RonM1254T cells with
both inhibitors revealed an accelerated degradation rate for the
mutant receptor, as compared with wild-type Ron (Fig. 6A).
Interestingly, RonM1254T degrada-
tion was paralleled by an evident
dephosphorylation of Akt and
Erk1/2 effectors (Fig. 6A). We fur-
ther evaluated the relative sensi-
tivity of wild-type and oncogenic
Ron to these inhibitory drugs in a
dose-response experiment. GA or
17-AAG concentration as low as 0.1
M was efficient in degrading the
mutant RonM1254T after 6 h of treat-
ment, whereas at least a 1 M con-
centration was required to induce
detectable degradation of the wild-
type receptor (Fig. 6B).
The destabilizing effects of GA
have been attributed to altered asso-
ciation of Hsp90 with its client pro-
teins (40). Therefore, we tested Ron
interaction with Hsp90 upon GA or
17-AAG treatment of 3T3-Ron and
3T3-RonM1254T cells in a short term
experiment (up to 60 min). In both
cell types, the receptor co-precipi-
tated with Hsp90, and geldanamy-
cins caused an evident decrease in
the amount of Hsp90 associated
with Ron immunocomplexes. How-
ever, the dissociation of the
RonM1254T-Hsp90 complex occurs
earlier, starting within 15 min of
drug exposure, as compared with
the Ron-Hsp90 complex (Fig. 7A).
Consistently, by using the lowest
effective concentration of GA and
17-AAG (0.1 M) able to induce
degradation of RonM1254T but not of
wild-type Ron, we observed dissoci-
ation of Hsp90 from the mutant
receptor only (Fig. 7B). These results
indicate that the oncogenic M1254T
substitution in the Ron receptor is
associated with increased sensitivity
to geldanamycins and with a more
dynamic interaction with Hsp90.
Geldanamycins Hamper Growth,
Migration, and Transforming Activ-
ity of Oncogenic Ron—The amino acid substitution M1254T
confers to Ron in vitro transforming potential, including
growth and migration in a ligand-independent way (10). We
tested if the GA derivative suitable for clinical use 17-AAG
could hamper these biological effects in 3T3-RonM1254T. In a
72-h proliferation assay, the higher proliferation rate of 3T3-
RonM1254T cells comparedwith 3T3-Ron cells was considerably
reduced in the presence of low concentrations (0.1 M) of
17-AAG. As expected, the growth rates of nontransformed 3T3
and 3T3-Ron cells were similar, and, consistently, the reduction
of growth rate observed in these cells upon 17-AAG was com-
FIGURE 7. Hsp90 dissociation from RonM1254T is more rapid and occurs at lower geldanamycin concen-
trations compared with wild-type receptor. A, 3T3-Ron and 3T3-RonM1254T cells were treated with vehicle
() or 1 M GA or with 1 M 17-AAG for the indicated times. Equal protein amounts of cell lysates were
subjected to immunoprecipitation (IP) with Ron antibodies, and associated Hsp90 was detected by immuno-
blotting (IB) with the appropriate antibodies. The immunoprecipitated receptor was detected by Ron immu-
noblotting. B, proteins from cell lysates of 3T3-Ron and 3T3-RonM1254T treated with vehicle () or increasing
amounts of GA or of 17-AAG for 6 h were subjected to Ron immunoprecipitation. Associated Hsp90 was
detected by immunoblotting with the appropriate antibodies. The immunoprecipitated receptor was
detected by Ron immunoblotting. All results shown are representative of at least three independent
experiments.
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parable. Immunoblotting analysis of Ron protein levels under
the same experimental conditions confirmed the higher sensi-
tivity of oncogenic RonM1254T to 17-AAG, even if degradation
of also the wild-type receptor occurred upon the prolonged
drug exposure (Fig. 8A).
In amigration assay, performed in the presence of serum, 3T3-
RonM1254T cellsmigratedmoreefficiently than3T3-Roncells.The
presence of 17-AAG hampered the haptotactic migration of both
cell types, and the inhibition was by far more evident in cells
expressing the Ron oncogenic form (Fig. 8B).
We have previously shown that RonM1254T has a strong
transforming activity when expressed in NIH-3T3 fibroblasts
(10). A focus-forming assay was performed in the presence or
absence of low doses of 17-AAG. As expected, RonM1254T-
transfected cells displayed a high transforming activity, which
was completely abolished by 17-AAG treatment (Fig. 8C).
We conclude that the clinically relevant inhibitor 17-AAG is a
potent negative regulator of cell proliferation, migration, and
transformation, typically induced by the RonM1254T oncogenic
form.
DISCUSSION
Ubiquitylation and down-regula-
tion represent a major deactivation
pathway for RTKs, whose impair-
mentmay be amechanism in cancer
(41).
Dysregulated signaling of Ron,
the tyrosine kinase receptor for
MSP, due to over-activation or loss
of negative regulation, is involved in
tumor progression and metastasis.
Overexpression and subsequent
aberrant activation of Ron have
been observed in primary breast
carcinomas (42), non-small cell lung
tumors (43), and colorectal adeno-
carcinomas (44). Silencing ron gene
expression by RNA interference has
been shown to hamper in vivo
tumor formation of established
colorectal carcinoma cells (45).
Moreover, it has been reported that
Ron expression is positively associ-
ated with histological grading,
larger size, and tumor stage in blad-
der cancer specimens (13).
We have previously demonstrated
a ligand-induced c-Cbl-dependent
mechanism for the down-regulation
of Ron (31). Here we identify a novel
degradation pathway for Ron. This
mechanism involves proteasomal
activity, the Hsp90/Hsc70 chaper-
ones and the U-box ubiquitin ligase
CHIP. The whole process of receptor
degradation is triggered by the small
molecule inhibitors of Hsp90 benzo-
quinone ansamycins via dissociation of the Ron-chaperone com-
plex. The requirement of this complex for Ron stability is
confirmed by the destabilizing effects observed also with the
Hsp90 inhibitor radicicol, which is chemically unrelated to
geldanamycins.
It has been reported that Hsp90 and its cohort of co-chaper-
ones play a regulatory role in conformationalmaturation and in
maintenance of structural integrity of a variety of cellular pro-
teins (17).We show here for the first time that Ron is present in
a stable but dynamic complex with the Hsp90/Hsc70-based
chaperone machinery, also containing the E3 ligase CHIP. As
shown for ErbB2 (20, 40), this complex is required formaintain-
ing Ron receptor stability. This is confirmed by the activity of
the Hsp90-inhibitory drugs geldanamycin or 17-AAG, which
force disruption of the Ron-Hsp90 interaction, followed by
receptor ubiquitylation and degradation.Moreover, conversely
to what occurs with c-Cbl-mediated degradation (31), geldana-
mycin does not require the Ron kinase activity for its action,
since the “kinase-dead” RonK1114M is highly sensitive to this
Hsp90 inhibitor.
FIGURE 8. 17-AAGpotently affects growth,migration, and transformationof cells expressing oncogenic
RonM1254T. A, NIH-3T3 fibroblasts (dotted curve), 3T3-Ron (dashed curve), and 3T3-RonM1254T (solid curve) cells
were plated on 96-well plates and cultured inmedium supplementedwith 10% fetal bovine serum inpresence
of vehicle (white symbols) or 100 nM17-AAG (black symbols). After 0, 24, 48, and 72hof drug addition, cellswere
fixedand stained in crystal violet, andabsorbanceat 595nmwasmeasured.OD is expressedasmeanA595S.E.
of three independent experiments (left panel). Protein levels from 3T3-Ron and 3T3 RonM1254T cell lysates were
determined by immunoblotting (IB) at same times and conditions of the growth curve (right panel). B, 3T3-Ron
and 3T3-RonM1254T cells were plated on the upper side of 8-mpore size Transwell chambers and allowed to
migrate for 6 h in the presence of vehicle (white columns) or 100 nM 17-AAG (black columns) toward the lower
chamber containing appropriate medium supplemented with 10% fetal calf serum and coated with fibronec-
tin. Cells thatmigrated toward the lower chamber were fixed and stained as described in A. OD is expressed as
meanA595S.E. of three independent experiments.C, NIH-3T3 fibroblastswere transfectedasdescribedunder
“Experimental Procedures” with Ron- or RonM1254T-encoding plasmid. Two days after transfection, vehicle
(white columns), 10 nM 17-AAG (hatched columns), or 50 nM 17-AAG (black columns) were added and renewed
every 48 h. Cell cultures were maintained at confluence and screened for focus formation 10 18 days after
transfection. Spontaneous formationof fociwasnegligible. All of the experimentswereperformed in triplicate,
and mean S.E. number of foci is displayed.
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The effect of geldanamycin has been restricted to the ability
of destabilizing newly synthesized EGFR or platelet-derived
growth factor receptormolecules (35, 46). On the other hand, it
has been also demonstrated that geldanamycin enhances the
loss of mature cell surface ErbB2 protein (40, 47), suggesting a
lack of univocal mean to target different receptors. Our results
clearly indicate that mature Ron exposed at plasma membrane
is a target of geldanamycin, as in the case of ErbB2. This is in
accordance with the association of mature Ron with the E3
ligase CHIP, which has been characterized as a mediator of
geldanamycin action for ErbB2 degradation (20, 47). How-
ever, based on our data, we cannot exclude that also the
uncleaved precursor of the Ron receptor may be affected by
geldanamycins.
Several evidences indicate that the ternary complex of the
substrates with chaperones and ubiquitin ligase is targeted to
the proteasome for degradation (16). Moreover, recently it has
been reported that proteasomal activity is required for ErbB2
internalization but that receptor degradation takes place in
lysosomes (48). Our results on Ron confirm that geldanamycin-
mediated receptor degradation requires the integrity of the
proteasomal pathway but that the lysosomal involvement is
dispensable.
A destabilizing effect of geldanamycins has been described
for the HGF/SF receptor Met, homologous to Ron (29, 49), but
the E3 ligase regulating this process has not been identified yet.
Conversely, our results clearly show that Ron is a substrate of
CHIP both in vitro and in vivo. Furthermore, by CHIP RNA
interference and by use of a truncated CHIP mutant, we dem-
onstrate that CHIP is necessary for Ron degradation, following
Hsp90 inhibition by geldanamycins.
This mechanism of Ron depletion is reminiscent of that shown
for ErbB2 (47) and for mutated EGFR (28). Also Ron can harbor
oncogenic mutations in a conserved region of the kinase domain
(10). One of these substitutions (M1254T) shifts substrate speci-
ficity and overcomes the requirement for the multifunctional
docking site (11).
We show here that the oncogenic RonM1254T receptor escapes
from c-Cbl mediated down-regulation. Notwithstanding it is effi-
ciently ubiquitylated and becomes degraded upon geldanamycin
treatment. Oncogenic Ron degradation occurs evenmore rapidly
than for the nonmutated receptor and at lower doses of theHsp90
inhibitor. The higher sensitivity of RonM1254T to geldanamycins
may be explained by the stronger interaction of RonM1254T with
Hsp90 and CHIP, compared with wild-type Ron. Similar results
wereobservedalso forEGFRmutants (28), v-Src (50), andmutated
p53 (51). As hypothesized for other kinases (28), the reason for the
greater associationof themutated receptor to the chaperone com-
plex, may reside more on a inherently less stable structure rather
than on its altered phosphorylation state.
The effect of Hsp90 inhibition by geldanamycin has been
thoroughly investigated and clarified in terms of altered
association of the chaperone to its client proteins, which are
thus degraded (52). In the case of ErbB2, geldanamycin activ-
ity has been associated to a parallel increase of Hsp/Hsc70
association to the receptor (20). We did not observe any
reciprocal exchange between Hsp90 and Hsc70 in the bind-
ing to either Ron or RonM1254T. On the other hand, we show
the first evidence of a marked and significant difference in
dissociation rate from Hsp90, between wild-type and onco-
genic Ron receptors, upon geldanamycins treatment. We
hypothesize that the ADP/ATP cycling rate of the Hsp90-
RonM1254T complex is higher than that of Hsp90 complex
containing Ron. This may explain the higher sensitivity of
the oncogenic mutant to geldanamycins. This highlights
RonM1254T as an ideal target for the antioncogenic activity of
these drugs.
Cells expressing oncogenic RonM1254T display ligand-inde-
pendent, strong constitutive Erk1/2 and phosphatidylinositol
3-kinase/Akt signaling, leading to elevated levels of growth and
migration. The less toxic GA-derivative 17-AAG markedly
inhibits these signaling pathways, resulting in a strong reduc-
tion of growth and migration rates, induced by oncogenic
RonM1254T signaling. We cannot exclude that degradation of
intracellular proteins, possibly RonM1254T effectors, may also
contribute to these effects. Nevertheless, this confirms the very
high sensitivity of the oncogenic receptor and of its signaling to
geldanamycins, resulting in robust inhibition of dysregulated
biological activities.
Recently, it has been demonstrated that geldanamycins
inhibit HGF/SF-dependent, urokinase-type plasminogen
activator-mediated cell scattering and invasion, thus affect-
ing typical tumor cell properties (30). Consistently, our
results demonstrate that 17-AAG abrogates the transform-
ing ability of oncogenic Ron. Even if further studies on xeno-
graphed immunodeficient mice are required to substantiate
the inhibition of Ron oncogenic properties, the overall
effects observed in cultured cells strongly suggest that Ron-
dependent tumorigenesis is a sensitive target of geldanamy-
cin or its derivatives. We identified a novel Ron destabiliza-
tion pathway, which highlights the important role of
ansamycin antibiotics as potential pharmacological tools,
able to target altered Ron expression and dysregulation in
cancers.
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